DIA’s conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2016 conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes.

This program has been developed in collaboration with the Study Endpoints Community.

Highlights

• Two Keynote Addresses! Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the FDA, and Dr. Mark McClellan, Director of the Duke Robert J. Margolis Center for Health Policy at Duke University, will share their perspectives on the development of study endpoints - Where are We Now and Where are We Going?
• Global speakers from regulatory agencies, industry, academia, and non-profit organizations

The Study Endpoints conference provided a lot of opportunities to speak to key decision makers at the FDA in an informal setting, which was very valuable to me and to many. The talks were also refreshing and provided information from different perspectives (industry, FDA, clinicians, patient advocacy, academics).
- 2015 Attendee

Network early and start engaging on social media using the hashtag #Endpoints16.